• Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021

    المصدر: Nasdaq GlobeNewswire / 06 مايو 2021 15:05:02   America/Chicago

    Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021

    RANCHO CUCAMONGA, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2021.

    First Quarter Highlights

    • Net revenues of $103.0 million for the first quarter
    • GAAP net income of $5.0 million, or $0.10 per share, for the first quarter
    • Adjusted non-GAAP net income of $13.6 million, or $0.27 per share, for the first quarter

    Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer commented: “The launch of glucagon, along with strong sales growth of Primatene Mist® and our epinephrine products, contributed to one of Amphastar’s strongest quarters in terms of sales growth to date. We expect that these core growth products will continue to drive growth for the remainder of the year, while we are confident in seeing our pipeline develop to diversify our portfolio.”

           
      Three Months Ended
      March 31, 
      2021 2020
         
      (in thousands, except per share data)
    Net revenues    $103,020    $84,688
    GAAP net income attributable to Amphastar $5,041 $3,949
    Adjusted non-GAAP net income attributable to Amphastar* $13,553 $8,383
    GAAP diluted EPS attributable to Amphastar stockholders $0.10 $0.08
    Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders* $0.27 $0.17

    _______________
    * Adjusted non-GAAP net income and Adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled “Non-GAAP Financial Measures” and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

    First Quarter Results

                 
      Three Months Ended       
      March 31,  Change 
      2021 2020 Dollars    % 
              
      (in thousands)   
    Net revenues:                        
    Primatene Mist® $18,383 $12,877 $5,506  43 %
    Epinephrine  15,578  3,990  11,588  290 %
    Enoxaparin  10,658  9,168  1,490  16 %
    Phytonadione  9,565  11,029  (1,464) (13)%
    Lidocaine  9,071  10,657  (1,586) (15)%
    Glucagon  7,984  —  7,984  N/A  
    Naloxone  6,341  8,875  (2,534) (29)%
    Other finished pharmaceutical products  20,302  24,702  (4,400) (18)%
    Total finished pharmaceutical products net revenues $97,882 $81,298 $16,584  20 %
    API  5,138  3,390  1,748  52 %
    Total net revenues $103,020 $84,688 $18,332  22 %

    Changes in net revenues were primarily driven by:

    • Primatene Mist® increased volumes resulting from:
      • The continued success of our nationwide television, radio, and digital marketing campaign
      • An increase in our distribution channels throughout 2020 and during the first quarter of 2021, including Target, which began selling Primatene Mist® in March 2021
    • Glucagon for injection emergency kit launched in February 2021
    • Epinephrine sales increased due to the launch of our approved epinephrine injection multi-dose vials during the second quarter of 2020 and a market shortage of the pre-filled syringes
    • Naloxone sales decreased due to lower average selling price because of increased competition
    • Other finished pharmaceutical product sales decreased due to lower demand, largely due to competitors returning to their normal distribution levels
                 
      Three Months Ended       
      March 31,  Change 
      2021  2020  Dollars    % 
                
      (in thousands)   
    Net revenues $103,020  $84,688  $18,332 22%
    Cost of revenues  58,074   47,865   10,209 21%
    Gross profit $44,946  $36,823  $8,123 22%
    as % of net revenues  44%   43%       

    Changes in the cost of revenues and the resulting increase in gross margin were primarily driven by:

    • Increased sales of higher margin products such as Primatene Mist®, epinephrine injection multi-dose vials, and glucagon
    • Partially offset by increased sales of low margin enoxaparin and higher input cost
                   
      Three Months Ended       
      March 31,  Change 
      2021 2020 Dollars    % 
              
      (in thousands)   
    Selling, distribution, and marketing $4,537  $3,294  $1,243  38 %
    General and administrative  15,338   10,746   4,592  43 %
    Research and development  14,765   15,303   (538) (4)%
    Non-operating expense, net  5,192   1,675   3,517  NM  
    • Selling, distribution, and marketing expenses increased due to the cost of our ongoing national television, radio, and digital marketing campaign for Primatene Mist®
    • General and administrative expenses increased primarily due to increased legal expenses, including a reserve of $1.3 million related to the settlement of employment litigation
    • Research and development expenses decreased due to lower clinical trial expenses, which was partially offset by an increase in salaries and personnel-related expenses as well as an increase in depreciation expense
    • We recorded an additional $4.4 million of expense relating to the litigation with Aventis

    Cash flow provided by operating activities for the three months ended March 31, 2021, was $22.8 million.

    Pipeline Information

    The Company currently has five ANDAs on file with the FDA targeting products with a market size of approximately $2.4 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and seven generic products in development targeting products with a market size of approximately $10 billion. This market information is based on IQVIA data for the 12 months ended March 31, 2021. The Company is currently developing multiple proprietary products with injectable and intranasal dosage forms.

    Amphastar’s Chinese subsidiary, ANP, currently has 17 Drug Master Files, or DMFs, on file with the FDA and is developing several additional DMFs.

    Company Information

    Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.

    Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, Primatene Mist®, Amphadase®, and Cortrosyn®, are the property of Amphastar.

    Non-GAAP Financial Measures

    To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) attributed to Amphastar and (ii) Adjusted non-GAAP diluted EPS attributed to Amphastar’s stockholders, which exclude amortization expense, share-based compensation, impairment charges, executive severance expense, and legal settlements, in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance because the Company’s management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

    Conference Call Information

    The Company will hold a conference call to discuss its financial results today, May 6, 2021, at 2:00 p.m. Pacific Time.

    To access the conference call, dial toll-free (877) 876-9177 or (785) 424-1672 for international callers, five minutes before the conference.

    The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.

    Forward Looking Statements

    All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance, backlog, sales and marketing of our products, market size and growth, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, our share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not facts but rather are based on Amphastar’s historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through our website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

    Contact Information:

    Amphastar Pharmaceuticals, Inc.
    Bill Peters
    Chief Financial Officer
    (909) 980-9484

    Table I
    Amphastar Pharmaceuticals, Inc.
    Condensed Consolidated Statement of Operations
    (Unaudited; in thousands, except per share data)

           
      Three Months Ended
      March 31, 
         2021
    		    2020
           
    Net revenues    $103,020     $84,688 
    Cost of revenues  58,074   47,865 
    Gross profit  44,946   36,823 
           
    Operating expenses:      
    Selling, distribution, and marketing  4,537   3,294 
    General and administrative  15,338   10,746 
    Research and development  14,765   15,303 
    Total operating expenses  34,640   29,343 
           
    Income from operations  10,306   7,480 
           
    Non-operating expense, net  (5,192)  (1,675)
           
    Income before income taxes  5,114   5,805 
    Income tax provision  1,155   2,280 
           
    Net income $3,959  $3,525 
           
    Net loss attributable to non-controlling interests $(1,082) $(424)
           
    Net income attributable to Amphastar $5,041  $3,949 
           
    Net income per share attributable to Amphastar stockholders:      
    Basic $0.11  $0.09 
    Diluted $0.10  $0.08 
           
    Weighted-average shares used to compute net income per share attributable to Amphastar stockholders:      
    Basic  47,520   46,408 
    Diluted  49,518   48,248 

    Table II
    Amphastar Pharmaceuticals, Inc.
    Condensed Consolidated Balance Sheet
    (Unaudited; in thousands, except per share data)

           
         March 31,     December 31, 
      2021
    		 2020
    ASSETS      
    Current assets:      
    Cash and cash equivalents $101,601  $92,642 
    Restricted cash  235   1,865 
    Short-term investments  13,531   12,977 
    Restricted short-term investments  2,200   2,200 
    Accounts receivable, net  77,938   66,005 
    Inventories  97,110   96,831 
    Income tax refunds and deposits  800   385 
    Prepaid expenses and other assets  6,749   6,777 
    Total current assets  300,164   279,682 
           
    Property, plant, and equipment, net  253,265   260,055 
    Finance lease right-of-use assets  594   612 
    Operating lease right-of-use assets  19,280   20,042 
    Goodwill and intangible assets, net  40,243   40,615 
    Other assets  7,212   5,250 
    Deferred tax assets  24,980   24,980 
    Total assets $645,738  $631,236 
           
    LIABILITIES AND STOCKHOLDERS' EQUITY      
    Current liabilities:      
    Accounts payable and accrued liabilities $108,545  $95,504 
    Income taxes payable  2,676   1,077 
    Current portion of long-term debt  12,173   12,263 
    Current portion of operating lease liabilities  3,702   3,357 
    Total current liabilities  127,096   112,201 
           
    Long-term reserve for income tax liabilities  4,709   4,709 
    Long-term debt, net of current portion  32,334   34,186 
    Long-term operating lease liabilities, net of current portion  16,464   17,464 
    Deferred tax liabilities  755   741 
    Other long-term liabilities  13,420   13,212 
    Total liabilities  194,778   182,513 
    Commitments and contingencies      
    Stockholders’ equity:      
    Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding  —   — 
    Common stock: par value $0.0001; 300,000,000 shares authorized; 55,184,000 and 47,718,003 shares issued and outstanding as of March 31, 2021 and 54,760,922 and 47,495,439 shares issued and outstanding as of December 31, 2020, respectively  6   5 
    Additional paid-in capital  413,926   410,061 
    Retained earnings  122,814   117,773 
    Accumulated other comprehensive loss  (5,642)  (3,721)
    Treasury stock  (125,546)  (121,812)
    Total Amphastar Pharmaceuticals, Inc. stockholders’ equity  405,558   402,306 
    Non-controlling interests  45,402   46,417 
    Total equity  450,960   448,723 
    Total liabilities and stockholders’ equity $645,738  $631,236 

    Table III
    Amphastar Pharmaceuticals, Inc.
    Reconciliation of Non-GAAP Measures
    (Unaudited; in thousands, except per share data)

          
     Three Months Ended
     March 31, 
     2021
    		    2020
          
    GAAP net income$3,959     $3,525 
    Adjusted for:     
    Intangible amortization 276   258 
    Share-based compensation 4,834   5,282 
    Impairment of long-lived assets 6   14 
    Reserves for litigation and settlements 5,695   — 
    Income tax (benefit) provision on pre-tax adjustments (2,229)  (1,004)
    Non-GAAP net income$12,541  $8,075 
          
    Non-GAAP net loss attributable to non-controlling interests$(1,012) $(308)
          
    Non-GAAP net income attributable to Amphastar$13,553  $8,383 
          
    Non-GAAP net income per share attributable to Amphastar stockholders:     
    Basic$0.29  $0.18 
    Diluted$0.27  $0.17 
          
    Weighted-average shares used to compute non-GAAP net income per share attributable to Amphastar stockholders:     
    Basic 47,520   46,408 
    Diluted 49,518   48,248 


                          
      Three Months Ended March 31, 2021
                     
        Selling, General  Research   Income Non-controlling
      Cost of  distribution and and Non-operating tax provision interest
         revenue    and marketing    administrative    development    expense, net    (benefit)    adjustment
    GAAP $58,074  $4,537  $15,338  $14,765  $5,192  $1,155 $(1,082)
    Intangible amortization  (242)  —   (34)  —   —   —  11 
    Share-based compensation  (1,146)  (127)  (2,968)  (593)  —   —  71 
    Impairment of long-lived assets  —   —   (6)  —   —   —  2 
    Reserves for litigation and settlements  —   —   (1,295)  —   (4,400)  —  — 
    Income tax provision (benefit) on pre-tax adjustments  —   —   —   —   —   2,229  (14)
    Non-GAAP $56,686  $4,410  $11,035  $14,172  $792  $3,384 $(1,012)


                          
      Three Months Ended March 31, 2020
                     
        Selling, General  Research   Income Non-controlling
      Cost of  distribution and and Non-operating tax provision interest
         revenue    and marketing    administrative    development    expense, net    (benefit)    adjustment
    GAAP $47,865  $3,294  $10,746  $15,303  $1,675  $2,280 $(424)
    Intangible amortization  (224)  —   (34)  —   —   —  11 
    Share-based compensation  (1,359)  (107)  (3,219)  (597)  —   —  127 
    Impairment of long-lived assets  (10)  —   (4)  —   —   —  1 
    Income tax provision (benefit) on pre-tax adjustments  —   —   —   —   —   1,004  (23)
    Non-GAAP $46,272  $3,187  $7,489  $14,706  $1,675  $3,284 $(308)

شارك على،